Cyanoacrylate Skin Adhesive After Mohs Surgery or Wide Local Excision
A Prospective Randomized Study of Surgical Site Infection After Linear Repair With or Without Cyanoacrylate Skin Adhesive Following Mohs Micrographic Surgery and Wide Local Excision
This study will compare surgical site infection after linear repair with or without cyanoacrylate skin adhesive following Mohs micrographic surgery or wide local excision.
Adult participants undergoing Mohs micrographic surgery or wide local excision for skin cancer with a surgical defect suitable for linear repair will be stratified by suture type and randomized to standardized running epidermal suture closure with or without cyanoacrylate skin adhesive.
The primary outcome is surgical site infection within 30 days after surgery. Secondary outcomes include scar quality, treatment satisfaction, wound care burden, wound healing characteristics, antibiotic use, culture results, health care utilization related to wound concerns, and adverse events.
Descripción general del estudio
Estado
Descripción detallada
Surgical site infection is an uncommon but clinically important complication after dermatologic surgery. Linear repairs are frequently performed after Mohs micrographic surgery and wide local excision, and closure technique may affect infection risk, wound healing, scar quality, and patient experience.
This is a prospective, randomized, stratified parallel group clinical study evaluating postoperative outcomes after standardized running epidermal suture closure with or without cyanoacrylate skin adhesive. Adult patients undergoing Mohs micrographic surgery or wide local excision for skin cancer will be screened on the day of surgery. Participants will be eligible if the surgical defect is suitable for linear repair using standardized running epidermal sutures.
Participants will be stratified by suture type. In the absorbable suture stratum, participants will be randomized using a 2×2 factorial design to fast gut or Vicryl Rapide suture material and to adhesive use or no adhesive. In the non-absorbable suture stratum, participants will receive Prolene and will be randomized to closure with or without cyanoacrylate skin adhesive.
All participants will undergo Mohs micrographic surgery or wide local excision as part of standard clinical care. Research procedures include randomization of closure approach, standardized wound photography, follow-up assessments at approximately 2 weeks and 3 months, documentation of infection or suspected infection, wound healing assessment, adverse event assessment, and patient-reported outcome measures.
The primary outcome is surgical site infection within 30 days following linear repair. Secondary outcomes include antibiotic use, wound healing metrics, patient-reported treatment satisfaction and wound care burden, scar quality using the Patient and Observer Scar Assessment Scale 3.0 Linear Scar Version, culture results and treatment descriptions when infection is suspected, health care utilization related to wound concerns, and adverse events.
Tipo de estudio
Inscripción (Estimado)
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Andrew Fay
- Número de teléfono: 612-625-8625
- Correo electrónico: afay@umn.edu
Copia de seguridad de contactos de estudio
- Nombre: Chandler Rundle, MD
- Número de teléfono: 612-625-8625
- Correo electrónico: rundle1@umn.edu
Ubicaciones de estudio
-
-
Minnesota
-
Minneapolis, Minnesota, Estados Unidos, 55420
- Oxboro Dermatology Clinic
-
Contacto:
- Andrew Fay
- Número de teléfono: 612-625-8625
- Correo electrónico: afay@umn.edu
-
Minneapolis, Minnesota, Estados Unidos, 55455
- University of Minnesota Dermatologic Surgery Clinic - CSC
-
Contacto:
- Andrew Fay
- Número de teléfono: 612-625-8625
- Correo electrónico: afay@umn.edu
-
Investigador principal:
- Chandler Rundle, MD
-
Minneapolis, Minnesota, Estados Unidos, 55455
- University of Minnesota Dermatologic Surgery Clinic - MG
-
Contacto:
- Andrew Fay
- Número de teléfono: 612-625-8625
- Correo electrónico: afay@umn.edu
-
Investigador principal:
- Chandler Rundle, MD
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Age 18 years or older
- Undergoing Mohs micrographic surgery or wide local excision for skin cancer
- Surgical defect suitable for linear repair
- Surgical defect suitable for linear repair using standardized running epidermal sutures
- Ability to provide informed consent
- Ability to read at a 5th grade level or above, needed for survey administration
Exclusion Criteria:
- Requirement for flap, graft, geometric repair, or healing by second intention
- Active infection or severe contamination at the surgical site prior to closure
- Known allergy or hypersensitivity to cyanoacrylate adhesive, fast gut, Vicryl Rapide, or Prolene
- Recurrent tumor at the surgical site
- Prior radiation therapy to the surgical site
- Current use of systemic antibiotics for an unrelated medical condition at the time of surgery
- Concurrent participation in another interventional research study that could confound wound healing or infection outcomes
- Inability to comply with study procedures or follow-up visits
- Any condition that, in the judgment of the investigator, would interfere with safe participation or interpretation of study outcomes
- Children
- Fetuses
- Neonates
- Prisoners
- Adults lacking capacity to consent or adults with diminished or fluctuating capacity to consent
- Non-English speakers
- Individuals unable to read
- Employees of the researcher
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Prevención
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Único
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Fast Gut Sutures With Adhesive
Participants in the absorbable suture stratum will receive standardized running epidermal closure using fast gut sutures followed by cyanoacrylate skin adhesive. |
Cyanoacrylate skin adhesive will be applied in a thin, continuous layer along the repaired wound after hemostasis and epidermal closure are complete. The adhesive is an FDA-approved topical wound closure product used within its labeled indication.
Otros nombres:
Standardized running epidermal closure will be performed using fast gut absorbable suture material after Mohs micrographic surgery or wide local excision. |
|
Comparador activo: Fast Gut Sutures Without Adhesive
Participants in the absorbable suture stratum will receive standardized running epidermal closure using fast gut sutures without cyanoacrylate skin adhesive. |
Standardized running epidermal closure will be performed using fast gut absorbable suture material after Mohs micrographic surgery or wide local excision. |
|
Experimental: Vicryl Rapide Sutures With Adhesive
Participants in the absorbable suture stratum will receive standardized running epidermal closure using Vicryl Rapide sutures followed by cyanoacrylate skin adhesive. |
Cyanoacrylate skin adhesive will be applied in a thin, continuous layer along the repaired wound after hemostasis and epidermal closure are complete. The adhesive is an FDA-approved topical wound closure product used within its labeled indication.
Otros nombres:
Standardized running epidermal closure will be performed using Vicryl Rapide absorbable suture material after Mohs micrographic surgery or wide local excision. |
|
Comparador activo: Vicryl Rapide Sutures Without Adhesive
Participants in the absorbable suture stratum will receive standardized running epidermal closure using Vicryl Rapide sutures without cyanoacrylate skin adhesive. |
Standardized running epidermal closure will be performed using Vicryl Rapide absorbable suture material after Mohs micrographic surgery or wide local excision. |
|
Experimental: Prolene Sutures With Adhesive
Participants in the non-absorbable suture stratum will receive standardized running epidermal closure using Prolene sutures followed by cyanoacrylate skin adhesive. |
Cyanoacrylate skin adhesive will be applied in a thin, continuous layer along the repaired wound after hemostasis and epidermal closure are complete. The adhesive is an FDA-approved topical wound closure product used within its labeled indication.
Otros nombres:
Standardized running epidermal closure will be performed using Prolene non-absorbable suture material after Mohs micrographic surgery or wide local excision. |
|
Comparador activo: Prolene Sutures Without Adhesive
Participants in the non-absorbable suture stratum will receive standardized running epidermal closure using Prolene sutures without cyanoacrylate skin adhesive. |
Standardized running epidermal closure will be performed using Prolene non-absorbable suture material after Mohs micrographic surgery or wide local excision. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Surgical Site Infection Within 30 Days After Linear Repair
Periodo de tiempo: Within 30 days after Mohs micrographic surgery or wide local excision
|
Surgical site infection will be assessed within 30 days following linear repair after Mohs micrographic surgery or wide local excision. Surgical site infection is defined as culture-confirmed infection or strong clinical suspicion of infection when a culture cannot be obtained, including purulent discharge, erythema with edema or warmth, drainage consistent with infection, or cellulitis requiring antibiotic therapy. |
Within 30 days after Mohs micrographic surgery or wide local excision
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Systemic Antibiotic Use
Periodo de tiempo: Baseline through 30 days after surgery
|
Prophylactic and postoperative systemic antibiotic use will be documented, including indication, timing, and duration. This includes antibiotics prescribed for suspected infection at follow-up or interval visits. |
Baseline through 30 days after surgery
|
|
Wound Healing Complications
Periodo de tiempo: 7 to 14 days and 30 days after surgery
|
Wound healing will be assessed by documenting dehiscence, necrosis, delayed epithelialization, and other healing-related complications. |
7 to 14 days and 30 days after surgery
|
|
Treatment Satisfaction
Periodo de tiempo: 2 weeks and 3 months after surgery
|
Treatment satisfaction will be assessed using the Oxford Skin Cancer Treatment Scale. |
2 weeks and 3 months after surgery
|
|
Wound Care Burden
Periodo de tiempo: 2 weeks after surgery
|
Wound care burden will be assessed using a brief custom wound-care questionnaire evaluating time spent on wound care, satisfaction with the wound-care regimen, and wound-care preference. |
2 weeks after surgery
|
|
Scar Quality
Periodo de tiempo: 3 months after surgery
|
Scar quality will be assessed using the Patient and Observer Scar Assessment Scale 3.0 Linear Scar Version. Participants will complete the patient scale, and a trained blinded assessor will complete the observer scale using standardized 3-month wound photographs. |
3 months after surgery
|
|
Culture Results and Infection Treatment
Periodo de tiempo: Within 30 days after surgery
|
For wounds with suspected infection, culture organisms, antibiotic selection, treatment course, and subsequent clinical course will be summarized descriptively. |
Within 30 days after surgery
|
|
Health Care Utilization Related to Wound Concerns
Periodo de tiempo: Baseline through 3 months after surgery
|
Urgent care visits, emergency department evaluations, specialty consultations, or hospitalizations related to postoperative infection or wound complications will be documented. |
Baseline through 3 months after surgery
|
|
Adverse Events
Periodo de tiempo: Baseline through 3 months after surgery
|
Adverse events will include hematoma, allergic or irritant contact dermatitis related to suture material or cyanoacrylate adhesive, and other unexpected surgical or wound-related adverse events. |
Baseline through 3 months after surgery
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Chandler Rundle, MD, University of Minnesota
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- DERM-2026-35119
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
producto fabricado y exportado desde los EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .